Rosmanol induces breast cancer cells apoptosis by regulating PI3K/AKT and STAT3/JAK2 signaling pathways

DONGJUN JIANG1*, JIAQI XU1, SITONG LII, MOUSSA IDE NASSER1, WEI WEI1, TIANJIAO MAO2, XINTONG LII3, XIAOPAN ZOU4, JIANG LI2* and XIAOMENG LI1*

1The Key Laboratory of Molecular Epigenetics of Ministry of Education (MOE), School of Life Sciences, Northeast Normal University, Changchun, Jilin 130024; 2Department of Stomatogy, Affiliated Stomatological Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510180, P.R. China; 3Bioprobe Application Research Unit, Chemical Biology Department, RIKEN-Max Planck Joint Research Division, Rikagaku KENkyusho/Institute of Physical and Chemical Research (RIKEN) Center for Sustainable Resource Science, Wako, Saitama 351-0198, Japan

Received August 14, 2020; Accepted June 7, 2021
DOI: 10.3892/ol.2021.12892

Abstract. Breast cancer is one of the most frequently diagnosed cancers amongst women; however, there is currently no effective treatment. Natural compounds are considered to contribute to cancer prevention and have a pivotal role in modulating apoptosis. Rosmanol is a phenolic diterpene compound with antioxidant and anti-inflammatory properties. In the present study, the effects of Rosmanol on breast cancer cell proliferation/apoptosis were investigated, and it was demonstrated that it inhibited the proliferation of MCF-7 and MDA-MB 231 cells but did not have a significant effect on normal human breast MCF-10A cells. In addition, the apoptotic process was accelerated by Rosmanol, through mitochondrial pathways and reactive oxygen species (ROS) production caused by DNA damage, which function further demonstrated by the attenuation and addition of the ROS inhibitor, N-acetyl-cysteine. It was also demonstrated that Rosmanol accelerated cell apoptosis, and arrested breast cancer cells in the S phase. Moreover, Rosmanol inhibited proliferation and promoted apoptosis of cancer cells via the inhibition of ERK and STAT3 signals, attributable to the increase in p-p38, the overexpression of protein inhibitor of activated STAT3, and the decrease in PI3K/AKT, ERK and JAK2/STAT3.

Introduction

Breast cancer is undoubtedly one of the most severe heterogeneous diseases affecting women worldwide, resulting in >500,000 deaths every year (1). Various efforts are being devoted to overcoming this critical issue, culminating in prevention, diagnosis, and treatment. More specifically, breast cancer can be treated by surgical, chemotherapeutic or radiotherapeutic methods that differ in their actions (2,3). Nevertheless, these approaches are effective only at the earlier stages, and because of their disadvantages, including high toxicity, side effects and inefficiencies for long-term use, they have failed to realize the cancer therapy (4).

Meanwhile, natural drugs have emerged as alternative methods to treat breast cancer because of their low side effects, high selectivity, safety and effectiveness. Some of the most promising natural anticancer drugs are phenolic compounds (5). The antitumor efficiency of natural phenolics has been associated with their strong anti-inflammatory and antioxidant activities and their ability to moderate molecular targets as well as signaling pathways, which are associated with cell differentiation (6). Rosmanol is a phenolic diterpene obtained from various plants, including Salvia officinalis, Hyptis incana and Rosmarinus. They have been used as potent antioxidants and anti-inflammatories due to their superoxide anion production inhibition capabilities as well as lipid peroxidation and free radical scavenging activities (7). Moreover, Rosmanol inhibited iNOS and COX-2 gene and protein expression as well as their downstream products, NO and PGE2, respectively (8), which causes decreased translocation of nuclear factor-xB (NF-xB) subunits (9). As previously reported, Rosmanol also inhibits the proliferation of human colon and neuroblastoma cancer (10).

In total, ~80% of breast cancers express the estrogen receptor α (ERα) and the progesterone receptor (PR). ER is a steroid hormone receptor, comprised of ERα and ERβ, in which the ERα content in cells is higher than that in normal breast tissue in estrogen-dependent breast cancers (11). Overexpression of ERβ and inhibition of ERα have been
shown to have anti-tumor effects against breast cancer in cells (12).

Moreover, the PI3K/AKT pathway serves an important role in breast cancer development (13). Estrogen receptor α-positive breast cancers adapt to hormone deprivation and acquire resistance to antiestrogen therapies. NF-κB is a downstream component of the PI3K/Akt pathway and is activated via phosphorylation of IkB kinase (IKK) (14).

Certain researchers have attempted to assess the function of JAK2 knockout in the acceleration of cell apoptosis, autophagy and inhibition of proliferation, and this is an important research direction for cancer therapy in the future (15-17). Notably, cytokines and growth factors unanimously use Janus kinase (JAK) as the signal transducer and further activate the [JAK/signal transducer and activator of transcription (STAT3)] pathway transcription (18). Additionally, STAT3 serves a key role in activating cell proliferation and growth in cancer cells, such as breast cancer cells (19). In addition to regulating STAT3, JAK2 signaling also regulates p38 and ERK signaling (20). The above are some important proliferation signals for breast cancer, which promote cell proliferation and inhibit cell apoptosis.

Despite its intense biological response, to the best of our knowledge the effects of Rosmanol on breast cancer have not been previously investigated. Accordingly, the present research aimed to investigate the effects of Rosmanol on proliferation and apoptosis in breast cancer, and to further reveal the associated mechanism by detecting the effects of Rosmanol on the p38, PI3K/Akt/ERK, and STAT3/JAK2 pathways.

Materials and methods

Cell culture. MCF-10A, MCF-7 and MDA-MB 231 cells were purchased from the American Type Culture Collection. Normal human breast MCF-10A cells were cultured in DMEM/F12 (1:1) media supplemented with 5% horse serum (Gibco; Thermo Fisher Scientific, Inc.), 1.2 mg/ml NaHCO 3 (Sigma-Aldrich; Merck KGaA) 500 ng/ml hydrocortisone (Sangon Biotech Co., Ltd.), 10 µg/ml human insulin (Gibco; Thermo Fisher Scientific, Inc.), 10 ng/ml human recombinant epidermal growth factor (Sigma-Aldrich; Merck KGaA) and 100 ng/ml cholera toxin (Sigma-Aldrich; Merck KGaA). The two human breast cancer cell lines, MCF-7 and MDA-MB 231, were cultured and maintained in DMEM containing 10% fetal bovine serum (FBS; Gibco, Thermo Fisher Scientific, Inc). The cells were cultured at 37˚C in a humidified atmosphere of 5% CO 2 and allowed to grow to a confluence of 70-80%.

Cell proliferation assay. MCF-10A, MCF-7 and MDA-MB 231 cells were harvested and seeded in a 96-well dish to a final concentration of 5x10 3 cells/well and incubated in DMEM containing 1% FBS for 24 h. Cells were treated with the indicated concentrations of Rosmanol (Baoji Herbest Bio-tech Co., Ltd.), then incubated for 48 h. Next, 20 µl MTT (Sigma-Aldrich; Merck KGaA) solution (5 mg/ml) was added to each well and incubated for 4 h at 37˚C. Finally, the medium was discarded, and 150 µl DMSO was added to each well. The plates were read at a wavelength of 570 nm using a Varioskan Flash Multimode Reader (Thermo Fisher Scientific, Inc.). Six duplicate wells were used for each treatment. The absorbance was measured at 570 nm, results were expressed as a percentage, relative to solvent-control incubations, and the IC 50 values were determined using non-linear regression analysis (percentage survival versus concentration).

Annexin V/PI assay for apoptosis. Apoptotic MCF-7 and MDA-MB 231 cells were investigated using the Annexin V/propidium iodide (PI) apoptosis detection kit (Beyotime Institute of Biotechnology) followed by flow cytometry, according to the manufacturer's protocol. MCF-7 and MDA-MB 231 cells (5x10 3 cells/well) were cultured in 6-well plates and treated with different concentrations (15, 30 and 60 µM) of Rosmanol for 48 h at 37˚C. Cells were harvested by trypsinization with no EDTA and washed twice with PBS and then stained with 5 µl Annexin V-FITC (Beyotime Institute of Biotechnology) and 10 µl PI in 500 µl binding buffer for 15 min at room temperature (RT) in the dark. Apoptotic cells were determined by using Cytomics FC 500 flow cytometer (Beckman Coulter Inc.) and the data were analysed using Cellquest analysis software v.3.0 (BD Biosciences).

Determination of MCF-7 and MDA-MB 231 cell apoptosis by immunofluorescence. MCF-7 and MDA-MB 231 apoptotic cell death was observed by DAPI staining. Briefly, cells were treated with 15, 30 and 60 µM Rosmanol for 48 h at 37˚C, then fixed with 4% paraformaldehyde for 20 min at 4˚C. Subsequently, cells were washed with precooled PBS (4˚C), twice with TBST (0.05% Tween20), and cells were stained with DAPI (1 µg/ml) at room temperature in the dark for 3 min, and washed with PBS. Apoptotic nuclei cells were observed under a fluorescent microscope (model IX71; Olympus Corporation).

Determination of MCF-7 and MDA-MB 231 cell cycle distribution. The cell cycle distributions in different phases after exposure to Rosmanol were analyzed by flow cytometry. In brief, MCF-7 and MDA-MB 231 cells (5x10 3 cells/well) were seeded into 6-well plates and exposed to 15, 30 and 60 µM Rosmanol for 48 h at 37˚C. Further, the cells were harvested, washed twice with PBS, and fixed with 70% ethanol for 2 h at 4˚C. After that, cells were centrifuged at 3,000 x g for 5 min at 4˚C and washed with PBS, resuspended in 500 µl of buffer containing 0.5 mg/ml RNase and 25 mg/ml propidium iodide (PI, Beyotime Institute of Biotechnology), and incubated in the dark at 37˚C for 15 min. The distribution of the cell cycle was determined by using Cytomics FC 500 flow cytometer (Beckman Coulter Inc.), and the data were analyzed using Cellquest analysis software v.3.0 (BD Biosciences).

Determination of reactive oxygen species (ROS) expression in MCF-7 and MDA-MB 231 cells. The generation of ROS was determined with 2,7-dichlorofluorescin diacetate (DCFH-DA) according to the manufacturer's protocol. Briefly, MCF-7 and MDA-MB 231 cells were cultured (5x10 3 cells/well) and then incubated with or without N-acetyl-cysteine (NAC) for 1 h at 37˚C. After the culture was treated with 15, 30 and 60 µM of Rosmanol for 48 h at 37˚C. The cells were collected, centrifuged at 600 x g for 4 min at room temperature, washed with PBS, resuspended in PBS containing 10 µM DCDFH-DA (Beyotime Institute of Biotechnology) and incubated in the
gel was transferred onto polyvinylidene fluoride membrane (PVDF). After the necessary transfer time, the membrane was blocked in 5% (w/v) non-fat milk and incubated for 1 h at room temperature. The membranes were incubated with appropriate primary antibodies, Caspase-3 (cat. no. 9662s), Caspase-8 (cat. no. 4927s), Caspase-9 (cat. no. 9502s), p-PI3k (cat. no. 4228), p-Akt (cat. no. 9271), Akt (cat. no. 9272), JAK2 (cat. no. 3230), p-JAK2 (cat. no. 3771), p-ERK (cat. no. 9101), p-p38 (cat. no. 9211), STAT3 (cat. no. 9139), p-STAT3 (cat. no. 9145), Bcl-2 (cat. no. 15071), Bax (cat. no. 2774), NF-KB (cat. no. 8242), Cox-2 (cat. no. 12282) (all 1:1,000; all Cell Signaling Technology, Inc.) and Cyclin A (cat. no. sc-271682), Cyclin B1 (cat. no. sc-245), Cyclin D1 (cat. no. sc-8396), Cyclin E1 (cat. no. sc-377100), ER-α (cat. no. sc8002) and ER-β (cat. no. sc-373853) (all 1:2,000; all Santa Cruz Biotechnology) at 4°C overnight and washed three times with a Tris-buffered saline-Tween solution (TBST) containing 0.05% Tween20. Finally, the blots were incubated with horseradish peroxidase-conjugated goat anti-mouse IgG (1:1,000; cat. no. sc-2005; Santa Cruz Biotechnology, Inc.) and horseradish peroxidase-conjugated goat anti-rabbit IgG (1:1,000; cat. no. sc-2004; Santa Cruz Biotechnology, Inc.) for 1 h at RT, washed with TBST for 30 min, and signals were detected using an ECL plus chemiluminescence kit on X-ray film (EMD Millipore) in a dark room or use Tanon 5500 high definition low illumination CCD system (Tanon Science & Technology Co., Ltd.) to detect blot signals and TanonImage software v.1.00 (Tanon Science & Technology Co., Ltd.) to capture and merge images. Protein bands were quantified by Image J software v.1.48 (National Institutes of Health).

**Western blot analysis of MCF-7 and MDA-MB 231 cells.** Protein expression regulation by Rosmanol was analyzed via western blotting and the data were analysed using Image J software v.1.48 (National Institutes of Health) following a protocol described previously (21) with a small modification. In brief, MCF-7 and MDA-MB 231 cells were seeded and incubated at 37°C for 24 h and were separated into 2 groups. Cells in one group were treated with 15, 30 and 60 μM Rosmanol for 48 h at 37°C and MCF-7 and MDA-MB 231 cells in the other group were pre-incubation with the caspase inhibitor Z-VAD-FMK (50 mM; Sigma-Aldrich; Merck KGaA) at 37°C for 1 h and then treated with Rosmanol (15, 30 and 60 μM) at 37°C for 48 h. The cells were then harvested and lysed with RIPA buffer. Afterward, the insoluble protein lysate was removed by centrifugation at 12,000 x g for 15 min at 4°C. Protein concentrations were determined using a NanoDrop 1000 (Thermo Fisher Scientific, Inc.). Proteins (40 μg/lane) were loaded on SDS-PAGE electrophoresis gel (10 or 12% according to the protein size), and the gel was transferred onto polyvinylidene fluoride membrane (PVDF). After the necessary transfer time, the membrane was blocked in 5% (w/v) non-fat milk and incubated for 1 h at room temperature. The membranes were incubated with appropriate primary antibodies, Caspase-3 (cat. no. 9662s), Caspase-8 (cat. no. 4927s), Caspase-9 (cat. no. 9502s), p-PI3k (cat. no. 4228), p-Akt (cat. no. 9271), Akt (cat. no. 9272), JAK2 (cat. no. 3230), p-JAK2 (cat. no. 3771), p-ERK (cat. no. 9101), p-p38 (cat. no. 9211), STAT3 (cat. no. 9139), p-STAT3 (cat. no. 9145), Bcl-2 (cat. no. 15071), Bax (cat. no. 2774), NF-KB (cat. no. 8242), Cox-2 (cat. no. 12282) (all 1:1,000; all Cell Signaling Technology, Inc.) and Cyclin A (cat. no. sc-271682), Cyclin B1 (cat. no. sc-245), Cyclin D1 (cat. no. sc-8396), Cyclin E1 (cat. no. sc-377100), ER-α (cat. no. sc8002) and ER-β (cat. no. sc-373853) (all 1:2,000; all Santa Cruz Biotechnology) at 4°C overnight and washed three times with a Tris-buffered saline-Tween solution (TBST) containing 0.05% Tween20. Finally, the blots were incubated with horseradish peroxidase-conjugated goat anti-mouse IgG (1:1,000; cat. no. sc-2005; Santa Cruz Biotechnology, Inc.) and horseradish peroxidase-conjugated goat anti-rabbit IgG (1:1,000; cat. no. sc-2004; Santa Cruz Biotechnology, Inc.) for 1 h at RT, washed with TBST for 30 min, and signals were detected using an ECL plus chemiluminescence kit on X-ray film (EMD Millipore) in a dark room or use Tanon 5500 high definition low illumination CCD system (Tanon Science & Technology Co., Ltd.) to detect blot signals and TanonImage software v.1.00 (Tanon Science & Technology Co., Ltd.) to capture and merge images. Protein bands were quantified by Image J software v.1.48 (National Institutes of Health).

**Transient transfection and luciferase reporter as say of MCF-10A, MCF-7 and MDA-MB 231 cells.** Luciferase assays were performed as previously described (22). Briefly, transient transfections were performed using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. Cells were seeded into 48-well plates (0.5x10^5 cells/well) at 37°C for 16 h before being transfected with 100 ng STAT3-Luc promoter in the presence of 25 ng Renilla Luciferase control pREP7 vector and incubated at 37°C for 24 h. The cells were then treated with Rosmanol at concentrations of 0, 15, 30 and 60 μM for...
24 h at 37°C. Firefly luciferase activities were calculated using the Dual-Luciferase reporter assay system (Promega Corporation) and the ratio of firefly luciferase activity to Renilla luciferase activity was defined as relative luciferase activity.

Statistical analysis. All statistical analyses were performed using Origin Lab software version 8.0 (OriginLab), and statistically significant differences between groups were determined by one-way ANOVA with Bonferroni’s post hoc test. P<0.05 was considered to indicate a statistically significant difference.

Results

Cytotoxicity of Rosmanol on breast cancer and normal cell lines. First, the effect of Rosmanol on cell viability was investigated using the MTT assay. The cells were incubated with 0, 6, 12.5, 25, 50, 100 and 200 µM Rosmanol. As shown in Fig. 1, Rosmanol was able to inhibit the proliferation of MCF-7 and MDA-MB 231 cells, suggesting that Rosmanol induced cytotoxicity against human breast cancer cells. It was revealed that Rosmanol induced cytotoxicity in MCF-7 and MDA-MB 231 cells not only in dose-dependent manner, but also in a time-dependent manner, with their
Rosmanol induces apoptosis in MCF-7 and MDA-MB 231 cells. To determine whether the cytotoxicity exerted by Rosmanol was due to apoptosis induction, morphological observations were first performed under a microscope. The exposure of MCF-7 and MDA-MB 231 cells to Rosmanol (15, 30 and 60 µM) for 48 h induced cell membrane changes along with a shift in their nuclear morphology, as well as DNA damage compared with untreated cells, as shown by DAPI staining. A measurement of apoptosis was determined by annexin V-FITC and PI double-staining flow cytometry, which can quantitatively assess early apoptosis (B4), late apoptosis (B2) and necrosis (B1). *P<0.05, **P<0.01 vs. control. MCF-7 and MDA-MB 231 cells were treated with Rosmanol (15, 30 and 60 µM) for 48 h in the presence or absence of caspase inhibitor Z-VAD-FMK, then the caspase levels were determined by western blotting. These cleaved-caspase and cleaved-PARP protein bands of MDA-MB-231 cells (top graph) and MCF-7 cells (bottom graph) were quantified and statistically analyzed (β-actin as an internal control). The data are presented as mean values ± SD of three independent experiments. *P<0.05 and ***P<0.001 vs. untreated group.

Figure 2. Rosmanol induces apoptosis in MCF-7 and MDA-MB 231 cells. (A) Morphological observation was firstly performed under a microscope. Exposure of MCF-7 and MDA-MB 231 cells to Rosmanol (15, 30 and 60 µM) for 48 h induces cell membrane changes along with a shift in their nuclear morphology, as well as DNA damage compared with untreated cells, as shown by DAPI staining. (B) A measurement of apoptosis was determined by annexin V-FITC and PI double-staining flow cytometry, which can quantitatively assess early apoptosis (B4), late apoptosis (B2) and necrosis (B1). *P<0.05, **P<0.01 vs. control. (C) MCF-7 and MDA-MB 231 cells were treated with Rosmanol (15, 30 and 60 µM) for 48 h in the presence or absence of caspase inhibitor Z-VAD-FMK, then the caspase levels were determined by western blotting. (D) These cleaved-caspase and cleaved-PARP protein bands of MDA-MB-231 cells (top graph) and MCF-7 cells (bottom graph) were quantified and statistically analyzed (β-actin as an internal control). The data are presented as mean values ± SD of three independent experiments. *P<0.05 and ***P<0.001 vs. untreated group.

Rosmanol induces apoptosis in MCF-7 and MDA-MB 231 cells. To determine whether the cytotoxicity exerted by Rosmanol was due to apoptosis induction, morphological observations were first performed under a microscope. The exposure of MCF-7 and MDA-MB 231 cells to Rosmanol (15, 30 and 60 µM) for 48 h induced cell membrane changes along with a shift in their nuclear morphology, as well as DNA damage compared
with untreated cells, as shown by DAPI staining. Within a certain range, the degree of apoptosis was more obvious as the Rosmanol concentration increased (Fig. 2A).

To verify the apoptosis induction by Rosmanol, a further measurement of apoptosis was determined by annexin V-FITC and PI double-staining flow cytometry, which can quantitatively assess early apoptosis (B4), late apoptosis (B2), and necrosis (B1). As shown in Fig. 2B, the B4 values increased with an increase in the Rosmanol concentration in both MCF-7 and MDA-MB 231 cells.

To further understand the molecular mechanism by which Rosmanol mediated apoptosis in MCF-7 and MDA-MB 231 cells, western blotting was conducted to detect caspases, the critical regulators of apoptosis (23,24). As illustrated in Fig. 2C and D, Rosmanol stimulated the activation of caspase-8, as well as caspase-9 which led to activated caspase-3 and consequently cleaved PARP, the major indicator enzyme of apoptosis. Furthermore, pre-incubation of MCF-7 and MDA-MB 231 cells with the caspase inhibitor Z-VAD-FMK (50 mM; Sigma-Aldrich; Merck KGaA) at 37˚C for 1 h and
then treated with Rosmanol (15, 30 and 60 µM) at 37°C for 48 h promoted the survival of the cells. These findings demonstrated that Rosmanol induced cancer cell apoptosis through extrinsic mitochondrial pathways.

Cytotoxicity mediated by Rosmanol is associated with generation of ROS. Immunostaining using DAPI revealed that Rosmanol induced DNA damage in MCF-7 and MDA-MB 213 cells. Previous studies reported that DNA damage induced oxidative stress in MCF-7 cells (25-27), which further resulted in the production of ROS (28). To evaluate whether the cytotoxicity mediated by Rosmanol was associated with the generation of ROS, MCF-7 and MDA-MB 231 cells were treated with Rosmanol, and then probed with the fluorescent DCF-DA for the detection and assessment of H$_2$O$_2$ by flow cytometry in the presence and absence of NAC for 48 h. The results indicated that the generation of intracellular H$_2$O$_2$ increased considerably with the treatment of Rosmanol (0, 15, 30 and 60 µM). In the meantime, supplementation with NAC rendered ROS production almost unaffected by Rosmanol (30  and 60 µM), which indicated a role of Rosmanol in the generation of H$_2$O$_2$, as illustrated in Fig. 3A. These results demonstrated that Rosmanol increases ROS in MCF-7 and MDA-MB 231 cells, and that cytotoxicity is associated with the generation of ROS.

Rosmanol stimulates apoptosis via the mitochondrial pathway. To validate our hypotheses, the effect of Rosmanol on mitochondrial depolarization was investigated in MCF-7 and MDA-MB 231 cells through the employment of Rhodamine 123 staining flow cytometry. Targeting mitochondria is a novel approach for cancer therapy because of their ability for stimulating apoptosis. In this regard, mitochondrial-mediated apoptosis can be highly regulated by counterbalancing the expression of pro-apoptotic, as well as anti-apoptotic, Bcl-2 proteins in which a loss in the mitochondrial transmembrane potential ($\Delta$$\psi$m) ensues in the case of the disruption of these counterbalances (29). As shown in Fig. 3B, Rosmanol treatment of MCF-7 and MDA-MB 231 cells induced the loss of mitochondrial membrane potential. This decrease in mitochondrial membrane potential by Rosmanol was particularly caused by the capability of Rosmanol to release mitochondrial Cytochrome c, a major factor in the formation of apoptosomes (9), and in addition, to induce Bax and inhibit Bcl-2, as shown in Fig. 3C and D. These findings indicate the role of Rosmanol in stimulating apoptosis via mitochondrial pathways.

Rosmanol induces activation of p38/MAPK and prohibition of ERK1/2 and PI3K/Akt in MCF-7 and MDA-MB 231 cells. ER, NF-κB and ERK signals are significant in breast cancer (30). First, the possibility of ER signals being involved in Rosmanol-induced apoptosis was investigated, and the expression of ERα and Erβ in MCF-7 ER-positive and MDA-MB231 ER-negative cells were analyzed via western blotting. It was revealed that Rosmanol did not induce ER expression in ER-negative MDA-MB231 cells, the data of which are not shown.

ERK1/2 is an important pathway regulating the signaling of multiple biological processes, such as cell proliferation and cell growth (31). The most classic signals in the ERK pathway are RAS and MAPK, and ERK is also activated by the AKT signal (32). p38/MAPK signaling is ubiquitous in normal and malignant cells and is activated in various cancer types (33). Certain studies have shown that the p38/MAPK pathway functions as a tumor suppressor by regulating tumor cell proliferation and transformation (34-38). The effect of Rosmanol on ERK signaling was investigated via western blotting, and it was revealed that the expression of p-ERK decreased significantly in MCF-7 and MDA-MB231 cells at

![Figure 4. Rosmanol induces apoptosis via activation of p38/MAPK and inhibition of ERK1/2 and PI3K/Akt in MCF-7 and MDA-MB 231 cells. (A) Western blotting tested p38/MAPK, ERK1/2 and Akt proteins expression in MCF-7 and MDA-MB 231 cells treated with varying concentrations of Rosmanol. (B) These protein bands were quantified and statistically analyzed (β-actin as an internal control). The data are presented as mean values ± SD of three independent experiments. *P<0.05, **P<0.01 and ***P<0.001 vs. untreated group. p-, phosphorylated.](image-url)
varying concentrations (Fig. 4A and B). Concurrently, the p-p38 and PI3K/AKT signals were detected, in particular the dramatically increased expression of p-p38 and reduced expression of p-Akt and p-PI3K (Fig. 4A and B). Accordingly, it was demonstrated that the upregulation of p-p38 and the downregulation of PI3K/AKT regulate ERK signaling to participate in the apoptosis caused by Rosmanol.

Rosmanol inhibits the JAK2/STAT3 pathway in MCF-7 and MDA-MB 231 cells. In tumors, STAT3 signaling is abnormally activated, which to drives the proliferation, survival, invasiveness, and metastasis of tumor cells, while strongly suppressing the apoptotic response (39). Subsequently, the effects of Rosmanol on the STAT3 pathway was investigated. Transient transfection and luciferase tests were conducted in MCF-7 and MDA-MB 231 cells to test the effects of Rosmanol on STAT3 transcription. Notably, Rosmanol significantly inhibited IL-6-induced STAT3 transcription in MCF-7 and MDA-MB 231 cells (Fig. 5A).

Protein inhibitor of activated STAT3 (PIAS3) was previously demonstrated to inhibit STAT3 transcriptional activity and promote growth inhibition in vitro (40). The regulation of PIAS3 expression by Rosmanol was then investigated in MCF-7 and MDA-MB 231 cells and found that Rosmanol induced increased PIAS3 expression in a dose-dependent manner (Fig. 5B and C). Rosmanol also decreased the level of phosphorylated STAT3 (Fig. 5B and C). The effect of Rosmanol on JAK2, the upstream signal of STAT3, was then investigated and it was revealed that it was significantly reduced (Fig. 5B and C). Therefore, it was demonstrated that Rosmanol inhibited the phosphorylation and transcription activity of STAT3 by augmenting PIAS3 or inhibiting the phosphorylation of JAK2.
Rosmanol induces S phase cell cycle arrest in MCF-7 and MDA-MB 231 cells. It was demonstrated that Rosmanol inhibits several cell proliferation signals and at the same time promotes the apoptosis of mitochondrial signals. In this situation, whether the cytotoxicity of Rosmanol has an effect on the cell cycle was investigated. Flow cytometry was conducted to...
check the cycle arrest in MCF‑7 and MDA‑MB 231 cells stimulated by Rosmanol (Fig. 6A and B), and the S phase showed a dose‑dependent increase in Rosmanol, while the G0/G1 and G2/M percentages decreased, respectively, for the same treatment concentration. This proves that Rosmanol promotes S phase arrest.

Cyclins have been demonstrated as activators of specific serine/threonine protein kinases, and are vital cell cycle regulatory proteins that promote the cell cycle process (41,42). Cyclin A is a marker in the S phase; it can activate two different cyclin‑dependent kinases (CDKs) and is expressed primarily in the S phase (43). To further elucidate the molecular mechanism underlying S phase arrest in MCF‑7 and MDA‑MB 231 cells, western blotting was performed to describe the cyclin proteins regulating the cell cycle. As shown in Fig. 6C and D, Rosmanol increased Cyclin A expression, yet suppressed the expression of Cyclin E, Cyclin D1 and Cyclin B1 (Fig. 6C and D). These results demonstrate that Rosmanol induces S phase arrest in MCF‑7 and MDA‑MB 231 cells.

Discussion

Rosmanol, an abundant natural product in the Salvia species, was demonstrated in the present study to promote breast cancer apoptosis in the mitochondrial pathway, simultaneously accelerating apoptosis and inhibiting cell proliferation via ERK and STAT3 signaling. It was also demonstrated that Rosmanol triggers oxidative stress in MCF‑7 and MDA‑MB231 cells and exerts anti-proliferation and mitochondrial apoptosis effects, depending on ROS‑induced DNA damage. Moreover, Rosmanol accelerated the process of apoptosis through S‑phase cell arrest. Moreover, it was found that Rosmanol induced apoptosis progression associated with the inhibition of STAT3 and ERK signaling, thereby preventing the proliferation of breast cancer MDA‑MB 231 cells.

Rosmanol was demonstrated to inhibit the proliferation of MCF‑7 and MDA‑MB 231 cells and increased the apoptosis rate of MCF‑7 and MDA‑MB 231 cells. Rosmanol induced MCF‑7 and MDA‑MB 231 cell cytotoxicity with an IC50 (51, 26 and 19 µM) and (42, 28 and 16 µM), respectively, for 24, 48 and 72 h. However, Rosmanol had no significant effect on MCF‑10A normal breast cells. Notably, Rosmanol promoted the apoptotic process, by activating cysteine protease or poly (ADP‑ribose) polymerase proteolysis in mitochondria, which further confirms that this process may be attenuated by the cysteine protease inhibitor Z‑VAD‑FMK. Rosmanol also stimulated apoptosis in human breast cancer MCF‑7 and MDA‑MB 231 cells. Flow cytometry revealed that Rosmanol increased ROS production which was attenuated by the manifestation of NAC. Furthermore, the generation of ROS is associated with improved cell apoptosis (44). These results affirmed the cytotoxicity of Rosmanol via the induction of ROS, an important apoptosis inducer, against human breast cancer MCF‑7 and MDA‑MB 231 cells.
Cell proliferation, autoregulated by the cell cycle, is regulated via a myriad of complex cyclin proteins (45), while cyclin B is required for cells to enter mitosis and G2/M transition (46). In addition, the S phase relies on a pathway to regulate Cyclin A synthesis (47). Here, it was demonstrated that the cytotoxicity of Rosmanol significantly inhibited the proliferation of cancer cells and that the channel of cells in the G1/S, to S phase was synchronized by cyclins. It was demonstrated that Rosmanol can stimulate MDA-MB 231 cell cycle arrest at the S phase by upregulating the expression of cyclin A and consequently downregulating the protein expression of Cyclin B1, Cyclin D1 and Cyclin E.

In tumor cells, ERK is often activated by Akt, and both of these Akt feedback signaling molecules serve a vital role in the proliferation and evasion of apoptosis in cells (48). A series of clinical trials are underway investigating the combined application of inhibitors that target the PI3K and MEK/ERK pathways, since single reagents have limited efficacy (49). The present study also demonstrated that Rosmanol functions as a potential natural antineoplastic alternative to the combination of Akt and ERK inhibitors, significantly inhibiting the Akt and ERK pathways, and considerably enhancing the antiproliferative effects of MCF-7 and MDA-MB 231 cells. NF-kB and Akt/ERK are two major cell-survival pathways that are often constitutively activated and communicate within cancer cells (50). p-p38 exerts a tumor suppressor effect. Here it was demonstrated that Rosmanol increases the expression of p-p38.

STAT proteins are critically involved in tumorigenesis in various cancers (51). PIAS3, the main cellular inhibitor of STAT3, has been described as a modulator of DNA-binding transcription factors (52). Activated JAKs phosphorylate STAT proteins, leading to their dimerization and translocation into the nucleus. In the nucleus, STATs act as transcription factors with pleiotropic downstream effects (53). In cancer cells, STAT3 activation leads to increased expression of downstream target genes, leading to increased cell proliferation (54). The present results showed that Rosmanol significantly inhibited IL-6-induced STAT3 transcription in MCF-7 and MDA-MB 231 cells, that the Rosmanol-induced increase in PIAS3 expression was dose-dependent and that Rosmanol inhibits JAK2 and STAT3 phosphorylation. It was demonstrated that Rosmanol augments PIAS3 expression and inhibits the JAK2/STAT3 pathway.

The overall findings of the present study are summarized in Fig. 7, demonstrating that Rosmanol triggers oxidative stress causes ROS-induced DNA damage, and serves an anti-proliferative role with a mitochondrial apoptotic effect in MCF-7 and MDA-MB 231 cells. Rosmanol causes cancer cell arrest at the S phase in the cell cycle. Furthermore, it was demonstrated that Rosmanol has effective antiproliferative and anticancer effects via the inhibition of JAK2/STAT3 and PI3K/AKT signals.

Acknowledgements

Not applicable.

Funding

This study was supported by the Ministry of Science and Technology (grant no. 2021YFE0108000 and 2016YFE0128500), the National Natural Science Foundation of China (grant no. 31870758), the Jilin Provincial Science & Technology Department (grant no. 20200201025JC).

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors’ contributions

DJ performed the cell and protein studies, analyzed the data, and drafted the manuscript. JX and SL participated in the cell and protein studies. MIN, XZ and XTL participated in analyzing the data, WW and TM performed cell cycle studies in MCF7 cells and cell apoptosis experiments by immunofluorescence in MDA-MB-231 cells after the article was submitted. JL and XML conceived the idea, designed the experiment, and drafted the manuscript. DJ and MIN confirmed the authenticity of all the raw data. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Draper L: Breast cancer: Trends, risks, treatments, and effects. AAOHN J 54: 445-453, 2006.
2. Bleicher RJ: Timing and delays in breast cancer evaluation and treatment. Ann Surg Oncol 25: 2829-2838, 2018.
3. Castanedo SA and Strasser J: Updates in the treatment of breast cancer with radiotherapy. Surg Oncol Clin N Am 26: 371-382, 2017.
4. Quintela-Fandino M, Soberon N, Lluch A, Manso L, Calvo I, Cortes J, Moreno-Antón F, Gil-Gil M, Martinez-Jánez N, Gonzalez-Martin A, et al: Critically short telomeres and toxicity of chemotherapy in early breast cancer. Oncotarget 8: 21472-21482, 2017.
5. Kuete V, Mjaveng AT, Nono EC, Simo CC, Zeino M, Nkengfack AE and Effert H: Cytotoxicity of seven naturally occurring phenolic compounds towards multi-factorial drug-resistant cancer cells. Phytomedicine 23: 856-863, 2016.
6. Lucas L, Russell A and Keast R: Molecular mechanisms of inflammation. Anti-inflammatory benefits of virgin olive oil and the phenolic compound oleocanthal. Curr Pharm Des 17: 754-768, 2011.
7. Petiwala SM and Johnson JJ: Diterpenes from rosemary (Rosmarinus officinalis): Defining their potential for anti-cancer activity. Cancer Lett 367: 93-102, 2015.
8. Lai CS, Lee JH, Ho CT, Liu CB, Wang JM, Wang YJ and Pan MH: Rosmanol potently inhibits lipopolysaccharide-induced iNOS and COX-2 expression through downregulating MAPK, NF-kappaB, STAT3 and C/EBP signaling pathways. J Agric Food Chem 57: 10990-10998, 2009.
9. Cheng AC, Lee MF, Tsai ML, Lai CS, Lee JH, Ho CT and Pan MH: Rosmanol potently induces apoptosis through both the mitochondrial apoptotic pathway and death receptor pathway in human colon adenocarcinoma COLO 205 cells. Food Chem Toxicol 49: 485-493, 2011.
10. Tabata K, Kim M, Makino M, Satoh M, Satoh Y and Suzuki T: Phenolic diterpenes derived from Hyptis incana induce apoptosis and Gr(2)/M arrest of neuroblastoma cells. Anticancer Res 32: 4779-4785, 2012.

11. Cheng M, Michalski S and Kommagani R: Role for growth regulation by estrogen in breast cancer 1 (GREB1) in hormone-dependent cancers. Int J Mol Sci 19: 2543, 2018.

12. Mishra AK, Abrahamsson A and Dabrosin C: Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of the AR. Oncotarget 7: 56876-56888, 2016.

13. Sharma VR, Gupta GK, Sharma AK, Batra N, Sharma DK, Joshi A and Sharma PK: PI3K/Akt/mTOR intracellular pathway and breast cancer: Factors, mechanism and regulation. Curr Pharm Des 23: 1633-1638, 2017.

14. Yu M, Qi B, Xiaoxiang W, Xu J and Liu X: Baxacile increases cisplatin sensitivity of A549 lung adenocarcinoma cells via PI3K/Akt/NF-κB pathway. Biomed Pharmacother 90: 677-685, 2017.

15. Voskas D, Ling LS and Woodgett JR: Signals controlling un-differentiated states in embryonic stem and cancer cells: Role of the phosphofurin 3 kinase pathway. J Cell Physiol 229: 1312-1322, 2014.

16. Huth HW, Albaranz JD, Torres AA, Bonjardim CA and Rogert C: MEK2 controls the activation of MKK3/MKK6-p38 axis involved in the MDA-MB-231 breast cancer cell survival: Correlation with cyclin D1 expression. Cell Signal 28: 1283-1291, 2016.

17. Heckler MM, Thakor H, Schafer CC and Riggins RB: ERK/MAPK regulates ERα expression, transcriptional activity and receptor-mediated tamoxifen resistance in ERα breast cancer. FEBS J 281: 2431-2442, 2014.

18. Harrison DA, Binari R, Nahreini TS, Gilman M and Perrimon N: Activation of a Drosophila Janus kinase (JAK) causes hemato poetic neoplasia and developmental defects. EMBO J 14: 2857-2865, 1995.

19. Zhang Z, Wang F, Du C, Gux H, Ma L, Liu X, Kormann M, Tian X and Yang Y: BRM/SMARCA2 promotes the proliferation and chemoresistance of pancreatic cancer cells by targeting JAK2/STAT3 signaling. Cancer Lett 402: 213-224, 2017.

20. Ho JM, Nguyen MH, Dierov JK, Badger KM, Beattie BK, Tartaro P, Haq R, Zanke BW, Carroll MP and Barber DL: TEL-JAK2 constitutively activates the extracellular signal-regulated kinase (ERK), stress-activated protein/Jun kinase (SAPK/JNK), and p38 signaling pathways. Blood 100: 1438-1448, 2002.

21. Nasser MI, Masood M, Wei W, Li X, Zhou Y, Liu B, Li J and Li X: Cordycepin induces apoptosis in SGC7901 cells via inhibition of PI3K/Akt and inhibited NS5a and STAT3 activation. Apoptosis 2016: 1302-1314, 2016.

22. Moulager M, Corellou F, Vergé V, Escande ML and Bouget FY: Concurrent blockade of NF-κB and Akt pathways: Structural and pharmacological perspectives. Eur J Med Chem 109: 314-341, 2016.

23. Timofeev O, Cizmecioglu O, Settele F, Kempf T and Hoffmann I: ERα and β hormone pathways: Structural and pharmacological perspectives. Eur J Med Chem 109: 314-341, 2016.

24. Lemons JI, Smith JK and Wang X: Concurrent blockade of NF-κB and Akt pathways potentiates cisplatin’s antitumor activity in vivo. Anticancer Drugs 23: 1039-1046, 2012.
51. Pastuszak-Lewandoska D, Domańska-Senderowska D, Kordiak J, Antczak A, Czarnecka KH, Migdalska-Sęk M, Nawrot E, Kiszalkiewicz JM and Brzeziańska-Lasota E: Immunoexpression analysis of selected JAK/STAT pathway molecules in patients with non-small-cell lung cancer. Pol Arch Intern Med 127: 758-764, 2017.

52. Yagil Z, Nechushtan H, Kay G, Yang CM, Kemeny DM and Razin E: The enigma of the role of protein inhibitor of activated STAT3 (PIAS3) in the immune response. Trends Immunol 31: 199-204, 2010.

53. Yang X, Tang Z, Zhang P and Zhang L: Research advances of JAK/STAT signaling pathway in lung cancer. Zhongguo Fei Ai Za Zhi 22: 45-51, 2019 (In Chinese).

54. Lu Y, Zhou J, Xu C, Lin H, Xiao J, Wang Z and Yang B: JAK/STAT and PI3K/AKT pathways form a mutual transactivation loop and afford resistance to oxidative stress-induced apoptosis in cardiomyocytes. Cell Physiol Biochem 21: 305-314, 2008.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.